Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Strong Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

HUTCHMED (China) Limited American Depositary Shares (HCM)

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/17/2016

Market Cap

3,228,387,837

Shares Outstanding

871,260,000

Weighted SO

174,251,254

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

EGRX --.--%

ANIP --.--%

PAHC --.--%

DCPH --.--%

PBH --.--%

PCRX --.--%

COLL --.--%

PROC --.--%

SSIC --.--%

Beta

0.7400

Last Div

0.0000

Range

11.934-21.92

Chg

-1.1250

Avg Vol

139996

Mkt Cap

3228387837

Exch

NASDAQ

Country

HK

Phone

852 2128 1188

DCF Diff

6.9986

DCF

12.8714

Div Yield

0.0000

P/S

3.4985

EV Multiple

-18.5857

P/FV

4.2855

Div Yield %

0.0000

P/E

-49.2359

PEG

-1.0719

Payout

0.0000

Current Ratio

2.8082

Quick Ratio

2.6838

Cash Ratio

0.5464

DSO

74.3050

DIO

27.4791

Op Cycle

101.7841

DPO

25.6785

CCC

76.1056

Gross Margin

0.3315

Op Margin

-0.1985

Pretax Margin

-0.1127

Net Margin

-0.0698

Eff Tax Rate

-0.0676

ROA

-0.0511

ROE

-0.0876

ROCE

-0.2064

NI/EBT

0.6193

EBT/EBIT

0.5677

EBIT/Rev

-0.1985

Debt Ratio

0.0651

D/E

0.1109

LT Debt/Cap

0.0699

Total Debt/Cap

0.0999

Int Coverage

0.0000

CF/Debt

-1.0913

Equity Multi

1.7037

Rec Turnover

4.9122

Pay Turnover

14.2142

Inv Turnover

13.2828

FA Turnover

9.7325

Asset Turnover

0.7319

OCF/Share

-0.5233

FCF/Share

-0.6883

Cash/Share

4.6871

OCF/Sales

-0.0971

FCF/OCF

1.3153

CF Coverage

-1.0913

ST Coverage

-3.3850

CapEx Coverage

-3.1721

Div&CapEx Cov

-3.1721

P/BV

4.2855

P/B

4.2855

P/S

3.4985

P/E

-49.2359

P/FCF

-27.3967

P/OCF

-35.3997

P/CF

-35.3997

PEG

-1.0719

P/S

3.4985

EV Multiple

-18.5857

P/FV

4.2855

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 04, 23:45 HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma GlobeNewswire Inc. May 13, 00:00 International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 GlobeNewswire Inc. Apr 22, 00:00 HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China GlobeNewswire Inc. Mar 19, 00:00 HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China GlobeNewswire Inc. Nov 22, 04:30 HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan GlobeNewswire Inc. Oct 16, 04:30 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial GlobeNewswire Inc. Aug 30, 04:30 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China GlobeNewswire Inc. Jun 17, 00:00 HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology GlobeNewswire Inc. Jun 03, 00:00 HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine GlobeNewswire Inc. May 24, 00:00 HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting GlobeNewswire Inc. Jan 16, 13:44 HCM Acquisition Corp. Announces Increase in Contribution Amount in Connection with its Proposed Extension GlobeNewswire Inc. Jan 10, 19:00 HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status GlobeNewswire Inc. Jan 10, 19:00 HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status GlobeNewswire Inc. Jan 10, 19:00 HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status GlobeNewswire Inc. Jan 10, 19:00 HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status GlobeNewswire Inc. Jan 10, 19:00 HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status GlobeNewswire Inc. Dec 12, 23:30 HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms GlobeNewswire Inc. Dec 12, 23:30 HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms GlobeNewswire Inc. Dec 12, 23:30 HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms GlobeNewswire Inc. Dec 12, 19:00 HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Revenue Product Segmentation